It is important to also note that quantitative analysis using MS-QMA was initially developed for newborn screening of fragile X syndrome in both sexes, targeting FMR1 promoter methylation,27,28 but was modified to also detect SNRPN promoter methylation in this study. The gene discussed is FMR1; the disease is fragile X syndrome.